Navigation Links
PharmAthene Reports First Quarter 2011 Financial and Operating Results
Date:5/11/2011

eration anthrax vaccine with potential for improved potency and stability
  • Valortim® - a fully human monoclonal antibody for the prevention and treatment of anthrax infection
  • rBChE - recombinant butyrylcholinesterase bioscavanger: Protexia®  and a second generation Advanced Expression System ("AES") countermeasures for nerve agent poisoning by organophosphorous compounds, including nerve gases and pesticides

  • Statement on Cautionary Factors Except for the historical information presented herein, matters discussed may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "potential"; "believe"; "anticipate"; "intend"; "plan"; "expect"; "estimate"; "could"; "may"; "should"; "will"; "project"; "potential"; or similar statements are forward-looking statements. PharmAthene disclaims any intent or obligation to update these forward-looking statements other than as required by law. Risks and uncertainties include risk associated with the reliability of the results of the studies relating to human safety and possible adverse effects resulting from the administration of the Company's product candidates, unexpected funding delays and/or reductions or elimination of U.S. government funding for one or more of the Company's development programs, the award of government contracts to our competitors, unforeseen safety issues, challenges related to the development, scale-up, technology transfer, and/or process validation of manufacturing processes for our product candidates, unexpected determinations that these product candidates prove not to be effective and/or capable of
    '/>"/>

    SOURCE PharmAthene, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related biology technology :

    1. PharmAthene to Host Year-End 2010 Earnings Conference Call and Webcast on Monday, March 28, 2011
    2. PharmAthene Strengthens Scientific Leadership and Program Management for Future Growth
    3. PharmAthene Receives FDA Clearance to Reinitiate Clinical Testing of Valortim®
    4. PharmAthene Reports Third Quarter 2010 Financial and Operational Results
    5. PharmAthene Receives Four Therapeutic Discovery Project Grants Totaling Approximately $850,000
    6. PharmAthene Announces Pricing of $15 Million Public Offering
    7. PharmAthene Announces Proposed Common Stock Offering
    8. PharmAthene Announces $3.9 Million Registered Direct Offering
    9. PharmAthene CEO To Participate on Biosecurity Panel at the 2010 BIO International Conference
    10. PharmAthene Appoints Mitchel Sayare, Ph.D. to the Companys Board of Directors
    11. PharmAthene Reports Year-End 2009 Financial and Operational Results and Provides Update On Ongoing Litigation With SIGA Technologies
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/24/2014)... MA (PRWEB) December 23, 2014 ... is designed to introduce cutting edge communication technology, ... of platform upgrades. This webinar series demonstrates online ... quest to leverage web conferencing’s most innovative and ...
    (Date:12/24/2014)... York (PRWEB) December 23, 2014 According to ... Long Island Affiliate of ITRA Global, the national office market ... steady recovery. This is evidenced by the third quarter’s ... stock market. Low energy costs have held inflation down ...
    (Date:12/24/2014)... Nashville Fertility Center announced that Dr. George A. ... Reproductive Medicine (ASRM), a leading professional organization committed to advancing ... role as treasurer, Dr. Hill also fills a seat on ... the mission of ASRM. , Dr. Hill has actively ...
    (Date:12/24/2014)... 23, 2014 Pipette.com announces their Holiday ... submit their #HolidayInTheLab pictures for a chance to win pipette-themed ... struggling to think of a holiday gift for their beloved ... the ideal holiday presents. The #HolidayInTheLab Contest encourages Pipette.com ...
    Breaking Biology Technology:SoundConnect Launches Leading Edge Business Communications Webinar Series 2SoundConnect Launches Leading Edge Business Communications Webinar Series 3ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 3Major Pipette Distributor Pipette.com Announces their Holiday in the Lab Contest 2
    ... Novavax, Inc. (Nasdaq: NVAX ) announced today ... company,s Chief Scientific Officer who will report to Dr. ...  Previously, Dr. Glenn was Chief Scientific Officer and founder of ... Johns Hopkins University,s School of Public Health and ...
    ... 2010 Olivier Bohuon will be,replacing Jean-Pierre Garnier ... , , , ... Olivier Bohuon , 51, was Executive Vice-President of the Abbott,Corporation and President ... Chicago ( $22 billion in sales).,In 2003, he was named ...
    ... , July 1 United Therapeutics Corporation ... (HKEx: 0950) announced today that they have entered into ... Injection in China .  Remodulin is a subcutaneously ... pulmonary arterial hypertension.  Lee,s Pharmaceutical is a leading Chinese ...
    Cached Biology Technology:Novavax Announces Appointment of Dr. Gregory Glenn as Chief Scientific Officer 2Novavax Announces Appointment of Dr. Gregory Glenn as Chief Scientific Officer 3Novavax Announces Appointment of Dr. Gregory Glenn as Chief Scientific Officer 4Olivier Bohuon Joins Pierre Fabre 2United Therapeutics and Lee's Pharmaceutical Sign Remodulin Distribution Agreement for China 2United Therapeutics and Lee's Pharmaceutical Sign Remodulin Distribution Agreement for China 3United Therapeutics and Lee's Pharmaceutical Sign Remodulin Distribution Agreement for China 4United Therapeutics and Lee's Pharmaceutical Sign Remodulin Distribution Agreement for China 5
    (Date:1/22/2015)... 22, 2015   EyeLock, Inc. , a market leader of ... Steve Gerber to the new role of Senior Vice ... leading development of mobile platforms and wearable solutions for EyeLock,s ... innovation in the semiconductor industry to his role at EyeLock, ...
    (Date:12/22/2014)... 2014 Holiday Season may be the brightest ever for ... the long anticipated floodgates for consumer biometrics may finally ... phones, tablets, and wearable mobile devices that incorporate biometrics ... with nearly 4.8 billion biometric devices by 2020.   ...
    (Date:12/17/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/s6qzt5/samsung_galaxy_s5 ) ... S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis" ... http://photos.prnewswire.com/prnh/20130307/600769 Based on a totally ... for the first time a fingerprint sensor in its ...
    Breaking Biology News(10 mins):EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 2First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 2Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2
    ... for splitting water into hydrogen and oxygen, driven by ... today, underpinning the long term potential of hydrogen as ... today are very inefficient and often require additional use ... important to establish new mechanisms by which water splitting ...
    ... eaten raw, fried and baked it even produces banana beer ... the fruit is only a small percentage of what the plant ... to rot as waste. Now scientists at The University of ... fuel, developing simple methods of producing banana briquettes that could be ...
    ... Three-day-old broccoli sprouts, a widely available human food, suppressed ... to a report in Cancer Prevention Research , a ... H. pylori infections are one of the most common ... cancer. The cancer protective effects of sulforaphane, a ...
    Cached Biology News:Weizmann Institute scientists develop a unique approach for splitting water into hydrogen and oxygen 2Weizmann Institute scientists develop a unique approach for splitting water into hydrogen and oxygen 3Going bananas for sustainable research -- scientists create fuel from African crop waste 2
    DITHIOTHREITOL, 150UMOL, 1 EA. Dithiothreitol (DTT), 0.1 M Solution:, *0.1 M solution of DTT in high purity dH2O., *0.2 m filtered., *Storage: -20C. Category: SEQUENASE....
    ... Varian Cary 50 Microplate Reader ... cost per analysis by extending ... the award-winning Cary 50 instruments. ... to 384 samples in microlitre ...
    ... Polynucleotide Kinase for labeling of 5' ... acids. In the exchange reaction T4 ... group from DNA to ADP and ... to the free 5' hydroxyl group ...
    ImageQuant 400, 1 EA. Category: ImageQuant CCD Imagers....
    Biology Products: